Entering text into the input field will update the search result below

Biohaven enrolls first patient in Phase 3 clinical trial of oral Rimegepant for the acute treatment of migraine

  • Biohaven Pharmaceutical (NYSE:BHVN) announces that it has commenced enrollment in the first of its two registrational Phase 3 clinical trials to evaluate the safety and efficacy of orally-dosed rimegepant (BHV-3000) for the acute treatment of migraine.
  • Enrollment in the second Phase 3 clinical trial is expected to begin this summer and topline results for both studies will be reported in 1H2018.
  • The co-primary endpoints of the studies are freedom from pain at two hours post-dosing and a demonstrated effect on nausea, photophobia or phonophobia.

Recommended For You

About BHVN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BHVN--
Biohaven Ltd.